JN Biosciences LLC

The antigen-specific immune response is a complex biological process that is negatively regulated by checkpoint molecules, such as PD-1, CTLA-4 and TIGIT, and positively regulated by costimulatory molecules, such as OX40, GITR and 4-1BB that belong to the TNF receptor super-family.  Blocking the function of PD-1 or CTLA-4 by an antagonistic monoclonal IgG antibody has been shown to be effective for immunotherapy of cancer in humans.

In addition to generating agonistic antibodies against costimulatory molecules for cancer immunotherapy, JN Biosciences has also generated antagonist antibodies against a variety of checkpoint molecules including, but not limited to, PD-1, PD-L1 and TIGIT.  These antibodies have been selected not only for their potent antagonist activity, but also for their superior developmentability, such as high expression, good stability and low immunogenicity.  Detailed characterization of these therapeutic antibody candidates is in progress.